Organization
University of Chicago Medicine
21 abstracts
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.Org: Duke Cancer Institute, University of California, San Francisco, University of Utah, University of California, Davis Comprehensive Cancer Center, University of Chicago Medicine,
Abstract
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,
Abstract
Clinical outcomes and efficacy of HER2-targeted therapy in breast cancer with uncommon in situ hybridization (ISH) patterns or discordant immunohistochemistry (IHC).Org: Department of Public Health Sciences, Section of Infectious Diseases and Global Health, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Medicine, Center for Data Intensive Science at the University of Chicago,
Abstract
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Instituto Valenciano de Oncología,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
Evaluation of drug tolerability as a function of toxicity and quality of life in patients enrolled on I-SPY2.Org: University of California, San Francisco Department of Surgery, University of California, San Francisco, Susan G. Komen, UCSF Breast Science Advocacy Core, Mayo Clinic - Department of Surgical Oncology,
Abstract
Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, University of Chicago Medical Center, Chicago, IL, University of Chicago, University of Illinois at Chicago,
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium.Org: Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, China, Northwestern Memorial Hospital, Chicago, IL, Chicago, IL, Il-Yang Pharmaceuticals, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer.Org: University of Chicago Medicine, University of Chicago, University of Chicago Medical Center, Chicago, IL,
Abstract
Intensity at the end of life in pediatric neuro-oncology patients: The case for pediatric palliative care.Org: University of Chicago, University of Chicago Medicine, Center for Data Intensive Science at the University of Chicago,
Abstract
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.Org: University of Chicago, University of Chicago Medicine, Northshore University Health System, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,
Abstract
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: Moffitt Cancer Center, University of Washington & Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, CHU Rennes, Université Rennes,
Abstract
Treatment and treatment-related toxicity following subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS).Org: University of Minnesota Masonic Cancer Center, Minneapolis, MN, St. Jude Children's Research Hospital, University of Chicago Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Northwestern Medicine Lake Forest Hospital,
Abstract
Impact of death anxiety (DA) on the psychological well-being and survival of patients with advanced cancer (ACP) in phase I trials and their spousal caregivers (SC).Org: University of Chicago Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Rosalind Franklin University of Medicine and Science Chicago Medical School,
Abstract
Alternative trastuzumab dosing schedules and association with health care greenhouse gas emissions.Org: VA Center for Clinical Management and Research, Yale College, Pritzker School of Medicine, University of Chicago Medicine, Committee on Clinical Pharmacology and Pharmacogenomics,
Abstract
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer.Org: University of Chicago Medicine, The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Chicago, UT Southwestern Medical Center, Center for Data Intensive Science at the University of Chicago,
Abstract
Racial differences in patterns of clinical trial discussion and participation among breast cancer patients at the University of Chicago.Org: Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, The University of Chicago Medicine Center for Advanced Care at Orland Park, Chicago, IL, Section of Hematology/Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
Symptom burdens in long-term survivors of gynecologic cancer receiving acupuncture care.Org: University of Chicago Medicine,